Investors often find themselves torn between two opposing camps: chasing high-growth names with nosebleed valuations or settling for cheap stocks that may lack momentum. The concept of "Growth at a Reasonable Price" (GARP) aims to bridge that divide, targeting companies that combine solid earnings expansion with valuation metrics that haven’t yet run away from reality. One systematic way to identify such candidates is through an Affordable Growth screen, which filters for stocks showing strong growth (a ChartMill Growth rating above 7), decent profitability and health scores, and a valuation that isn’t excessive (a ChartMill Valuation rating above 5). By requiring all three pillars, the screen avoids speculative plays and focuses on businesses that are both expanding and reasonably priced relative to their fundamentals.
Vericel Corp (NASDAQ:VCEL) stands out as a prime example of this strategy in action. The company focuses on patient-specific cellular therapies and specialty biologics, with a commercial portfolio including MACI for knee cartilage repair, Epicel for severe burns, and the licensed NexoBrid for burn eschar removal. It operates in the competitive biotechnology space, yet the fundamental report reveals a company that checks nearly every box for an affordable growth thesis.
Growth: Strong Past and Promising Future
The growth pillar is where Vericel truly shines. Over the past year, earnings per share surged by an impressive 1,300%, while revenue expanded by 22.45%. Looking at a longer horizon, EPS grew at an average annual rate of 44.04% and revenue at 17.34%. Those figures are well above what most companies in any industry can claim. Critically, forward estimates indicate this momentum will continue: EPS is expected to grow by 49.37% per year on average, and revenue by 19.38% annually. The growth trajectory is also described as stable, meaning the expansion rate isn’t expected to decelerate sharply. For an Affordable Growth screen, this kind of sustained, high-momentum growth is exactly the kind of catalyst that justifies a premium valuation.
Valuation: Reasonable in Context
At first glance, the valuation metrics look steep. Vericel’s trailing Price/Earnings ratio stands at 102.14, far above the S&P 500 average of 26.95. But context matters. Within the biotechnology industry, the average P/E is about 36.45, and Vericel actually trades cheaper than 90.25% of its industry peers. The forward P/E of 48.00 is also well below the industry average forward P/E of 30.47, meaning the market is pricing in the expected earnings growth. The PEG ratio (which compares P/E to growth) signals that the stock isn't cheap on a pure growth-adjusted basis, but the outstanding profitability rating helps justify the higher multiple. More importantly, other valuation measures paint a more attractive picture: the Enterprise Value to EBITDA ratio is cheaper than 89.47% of peers, and the Price to Free Cash Flow ratio is cheaper than 91.23% of peers. For a GARP investor, this suggests the stock isn’t wildly overpriced relative to its sector, and the strong growth narrative helps bridge the gap.
Profitability: A Strong Foundation
Growth is meaningless if the company can’t turn revenue into profits, but Vericel’s profitability rating of 8 out of 10 indicates it does exactly that. The company generated positive earnings in the past year and maintains positive operating cash flow. Return on Assets (4.42%), Return on Equity (6.02%), and Return on Invested Capital (2.84%) all rank among the top 10% of biotechnology peers. The profit margin of 7.35% and operating margin of 5.40% are both strong for the industry, and each has been improving over the last several years. The gross margin of 74.84% is also well above average and rising. For the Affordable Growth strategy, solid profitability ensures that growth is not coming at the expense of financial viability—the company is actually generating returns on its investments.
Health: Low Debt and Strong Liquidity
Financial health is often the overlooked third leg of the GARP stool. Vericel earns a health rating of 7 out of 10, and the underlying data is even stronger. The Altman-Z score of 10.25 points to virtually no bankruptcy risk, and the company carries essentially no debt—debt to equity is 0.00, and the debt to free cash flow ratio is a minuscule 0.01 (meaning it could pay off all debt in a matter of days). Current and quick ratios are both above 4.7, indicating ample liquidity for short-term obligations. The only cautions are that the return on invested capital is below the cost of capital (a sign of value destruction), and the company has slightly more shares outstanding than a year ago due to dilution. But overall, this is a business with a fortress-like balance sheet—a key requirement for any stock that promises sustainable growth.
For a complete breakdown of the underlying metrics, you can review the full fundamental analysis report on Vericel Corp.
Verdict: A Classic Affordable Growth Candidate
Vericel brings together high and sustainable growth in both revenue and earnings, a valuation that—while not bargain-basement—is reasonable compared to its industry peers and supported by strong profitability, and a healthy balance sheet free of problematic debt. The Affordable Growth screen is designed to surface exactly this profile: companies that can deliver expansion without demanding heroic valuation assumptions. While no stock is without risks—especially in the volatile biotech space—the fundamental scores here suggest Vericel offers a favorable risk/reward proposition for GARP-minded investors.
If you’re interested in finding more stocks that meet these same criteria, the same screen that surfaced Vericel can be applied to the broader market. You can run the full Affordable Growth screen here to explore additional candidates that combine strong growth with reasonable valuations and solid fundamentals.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial professional before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
Vericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotech
Investors often find themselves torn between two opposing camps: chasing high-growth names with nosebleed valuations or settling for cheap stocks that may lack momentum. The concept of "Growth at a Reasonable Price" (GARP) aims to bridge that divide, targeting companies that combine solid earnings expansion with valuation metrics that haven’t yet run away from reality. One systematic way to identify such candidates is through an Affordable Growth screen, which filters for stocks showing strong growth (a ChartMill Growth rating above 7), decent profitability and health scores, and a valuation that isn’t excessive (a ChartMill Valuation rating above 5). By requiring all three pillars, the screen avoids speculative plays and focuses on businesses that are both expanding and reasonably priced relative to their fundamentals.
Vericel Corp (NASDAQ:VCEL) stands out as a prime example of this strategy in action. The company focuses on patient-specific cellular therapies and specialty biologics, with a commercial portfolio including MACI for knee cartilage repair, Epicel for severe burns, and the licensed NexoBrid for burn eschar removal. It operates in the competitive biotechnology space, yet the fundamental report reveals a company that checks nearly every box for an affordable growth thesis.
Growth: Strong Past and Promising Future
The growth pillar is where Vericel truly shines. Over the past year, earnings per share surged by an impressive 1,300%, while revenue expanded by 22.45%. Looking at a longer horizon, EPS grew at an average annual rate of 44.04% and revenue at 17.34%. Those figures are well above what most companies in any industry can claim. Critically, forward estimates indicate this momentum will continue: EPS is expected to grow by 49.37% per year on average, and revenue by 19.38% annually. The growth trajectory is also described as stable, meaning the expansion rate isn’t expected to decelerate sharply. For an Affordable Growth screen, this kind of sustained, high-momentum growth is exactly the kind of catalyst that justifies a premium valuation.
Valuation: Reasonable in Context
At first glance, the valuation metrics look steep. Vericel’s trailing Price/Earnings ratio stands at 102.14, far above the S&P 500 average of 26.95. But context matters. Within the biotechnology industry, the average P/E is about 36.45, and Vericel actually trades cheaper than 90.25% of its industry peers. The forward P/E of 48.00 is also well below the industry average forward P/E of 30.47, meaning the market is pricing in the expected earnings growth. The PEG ratio (which compares P/E to growth) signals that the stock isn't cheap on a pure growth-adjusted basis, but the outstanding profitability rating helps justify the higher multiple. More importantly, other valuation measures paint a more attractive picture: the Enterprise Value to EBITDA ratio is cheaper than 89.47% of peers, and the Price to Free Cash Flow ratio is cheaper than 91.23% of peers. For a GARP investor, this suggests the stock isn’t wildly overpriced relative to its sector, and the strong growth narrative helps bridge the gap.
Profitability: A Strong Foundation
Growth is meaningless if the company can’t turn revenue into profits, but Vericel’s profitability rating of 8 out of 10 indicates it does exactly that. The company generated positive earnings in the past year and maintains positive operating cash flow. Return on Assets (4.42%), Return on Equity (6.02%), and Return on Invested Capital (2.84%) all rank among the top 10% of biotechnology peers. The profit margin of 7.35% and operating margin of 5.40% are both strong for the industry, and each has been improving over the last several years. The gross margin of 74.84% is also well above average and rising. For the Affordable Growth strategy, solid profitability ensures that growth is not coming at the expense of financial viability—the company is actually generating returns on its investments.
Health: Low Debt and Strong Liquidity
Financial health is often the overlooked third leg of the GARP stool. Vericel earns a health rating of 7 out of 10, and the underlying data is even stronger. The Altman-Z score of 10.25 points to virtually no bankruptcy risk, and the company carries essentially no debt—debt to equity is 0.00, and the debt to free cash flow ratio is a minuscule 0.01 (meaning it could pay off all debt in a matter of days). Current and quick ratios are both above 4.7, indicating ample liquidity for short-term obligations. The only cautions are that the return on invested capital is below the cost of capital (a sign of value destruction), and the company has slightly more shares outstanding than a year ago due to dilution. But overall, this is a business with a fortress-like balance sheet—a key requirement for any stock that promises sustainable growth.
For a complete breakdown of the underlying metrics, you can review the full fundamental analysis report on Vericel Corp.
Verdict: A Classic Affordable Growth Candidate
Vericel brings together high and sustainable growth in both revenue and earnings, a valuation that—while not bargain-basement—is reasonable compared to its industry peers and supported by strong profitability, and a healthy balance sheet free of problematic debt. The Affordable Growth screen is designed to surface exactly this profile: companies that can deliver expansion without demanding heroic valuation assumptions. While no stock is without risks—especially in the volatile biotech space—the fundamental scores here suggest Vericel offers a favorable risk/reward proposition for GARP-minded investors.
If you’re interested in finding more stocks that meet these same criteria, the same screen that surfaced Vericel can be applied to the broader market. You can run the full Affordable Growth screen here to explore additional candidates that combine strong growth with reasonable valuations and solid fundamentals.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial professional before making any investment decisions.
Read full article here »